Giles Platford/LinkedIn
Dec 12, 2025, 09:34
Giles Platford on Baby Big: Plasma-Derived Drug Against Infant Botulism
Giles Platford, President, Plasma-Derived Therapies Business Unit at Takeda and Chair of the Global Executive Board at PPTA, shared on LinkedIn:
”Plasma-derived therapies are often the only effective treatment for patients with certain rare and complex, chronic conditions.
One case in point is infant botulism: in partnership with the California Department of Public Health, on a non-profit basis, Takeda produces the only FDA-approved treatment for this condition, Baby Big.
The recent outbreak of infant botulism in the U.S. has put a fine point on the importance of this therapy.
Learn more in this story from The Independent”
Stay updated with Hemostasis Today.
-
Jan 29, 2026, 14:02Emma Lefrancais on Alarmin IL33 and Platelet Biology
-
Jan 29, 2026, 13:44Sia A: One of My Favorite Conversations from ASH
-
Jan 29, 2026, 13:34Sarah Matuja on Tanzania Stroke Project
-
Jan 29, 2026, 13:28Nancy Di Salvo on Amplifying Rare Disease Voices Through Partnership
-
Jan 29, 2026, 13:21Raul Santos Shares The Results of ORION-16: On The Efficacy and Safety of Inclisiran
-
Jan 29, 2026, 05:22Aravind Palraj Draws a Comparison Between APS and Lupus Cerebritis
-
Jan 29, 2026, 05:09Edina Cenko on Expanding Cardiovascular Risk: From Ischaemia to Emerging Frontiers
-
Jan 29, 2026, 04:58Anna Randi Shares the Latest Episode of The VWF and Angiogenesis Story from Her Lab
-
Jan 29, 2026, 04:49Ruah Alyamany on Her Contribution to Establishing The Role of IgM in APS